
    
      -  To determine the maximum tolerated dose (MTD) of temsirolimus that could be administered
           weekly in combination with pemetrexed.

        -  To determine the dose-limiting toxicity (DLT) of temsirolimus and pemetrexed as well as
           other toxicities of this combination therapy.

        -  To describe the response rate of the combination in patients with relapsed/refractory
           non-small cell lung cancer (NSCLC).

        -  To describe phospho-Akt and phospho-S6 levels in circulating mononuclear cells before
           and after treatment.

        -  To determine the response rates in patients with NSCLC when treated with temsirolimus
           and pemetrexed.

        -  To evaluate progression-free survival in patients with NSCLC when treated with
           temsirolimus and pemetrexed.

        -  To determine the one-year survival rates in patients with NSCLC when treated with
           temsirolimus and pemetrexed.

        -  To describe phospho-Akt and phospho-S6 levels in circulating mononuclear cells before
           and after treatment.
    
  